Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
24/06/2026 20:00
BRIEF-Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia June 24 (Reuters) - Ionis Pharmaceuticals Inc IONS.O:
TRYNGOLZA® (OLEZARSEN) APPROVED BY THE FDA AS THE FIRST AND ONLY TREATMENT TO REDUCE TRIGLYCERIDES AND THE RISK OF ACUTE PANCREATITIS IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG)
IONIS PHARMACEUTICALS - TRYNGOLZA AVAILABLE IN 50 MG OR 80 MG DOSE, SELF-ADMINISTERED MONTHLY
IONIS PHARMACEUTICALS - TRYNGOLZA TO BE AVAILABLE IN U.S. FOR SHTG IN JULY
Source text: ID:nBw9X7BDLa
Further company coverage: IONS.O
Recent news on Ionis Pharmaceuticals
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study